Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
暂无分享，去创建一个
O. Vasiljeva | M. Belvin | W. Kavanaugh | D. Daniel | B. Irving | V. Rangan | B. Howng | K. Tipton | J. West | J. Sagert | M. Paidhungat | Kenneth R. Wong | Victoria Singson | Chihunt Wong | C. Chan | Shouchun Liu | J. Richardson | L. Diep | Michael Krimm | Margaret Nguyen | Ruth Villanueva | L. Mei | A. Jang | J. Razo | H. Assi | Nicole Lapuyade | Bruce Howng